Login Register Cart 0
Generic placeholder image

Current Nutrition & Food Science

Editor-in-Chief

ISSN (Print): 1573-4013
ISSN (Online): 2212-3881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Glucosamine Sulphate Potassium Chloride in the Management of Osteoarthritis- Considering Emulgel Dosage Form: A Review

Author(s): Komal Rao and Neha Minocha*

Volume 19, Issue 4, 2023

Published on: 17 October, 2022

Page: [419 - 427] Pages: 9

DOI: 10.2174/1573401318666220601150053

Price: $65

conference banner
Abstract

Background: In addition to lifestyle, diet, environmental, and physiological factors, genetics also contributes to an increase in mitochondrial vulnerability. With depression, the hypothalamic, pituitary, and adrenal (HPA) axis are overactive, which is linked to higher CNS glucocorticoid levels. In recent years, topical drug delivery has been used on a priority basis compared to other drug delivery systems because of its specific site action and sustained release capacity. An emulsion gel is prepared by an emulsion incorporated into a gel by a gelling agent. Glucosamine Sulphate Potassium Chloride (GSPC) is used to treat osteoarthritis. It does this by increasing the production of proteoglycans, which can cause the cartilage to break down.

Objectives: The aim behind choosing the glucosamine sulphate potassium chloride for the management of Osteoarthritis (OA) is that it has many clinical investigations and has topical properties which are effective against osteoarthritis.

Methods: Osteoarthritis is a prevalent rheumatic musculoskeletal disorder. It is a pervasive disorder affecting people worldwide and can affect any joint, mainly the knees, hips, spine, and hand joints. The review is based on many studies extracted from Google Scholar, Google Patents, etc. Data from other sources were gathered to do further research on osteoarthritis.

Results: Extensive literature was studied about Glucosamine Sulphate Potassium Chloride. It has been shown that GSPC is effective against osteoarthritis, and also, some patents regarding GSPC have a therapeutic effect on making our joints healthy.

Conclusion: Topical formulations are widely used for better patient compliance, and emulgel is a good choice regarding viscosity and spreadability. GSPC is effective against osteoarthritis; many clinical studies have evidence of this.

Keywords: Nano-formulations, emulgel, topical drug delivery, glucosamine sulphate, glucosamine sulphate potassium chloride, drug.

« Previous Next »
Graphical Abstract

[1]
Thomas J, Kuppuswamy S, Sahib A, Benedict A, George E. A review on emulgel as a current trend in topical drug delivery systems. Int J Pharm Res 2017; 9(3): 273-81.
[2]
Yadav S, Mishra M, Tiwari A, Shukla A. Emulgel: A new approach for enhanced topical drug delivery. Int J Curr Pharm Res 2017; 9(1): 15-9.
[http://dx.doi.org/10.22159/ijcpr.2017v9i1.16628]
[3]
Charyulu N, Joshi P, Dubey A, Shetty A. Emulgel: A boon for enhanced topical drug delivery. Journal of Young Pharmacists 2021; 13: 76-9.
[http://dx.doi.org/10.5530/jyp.2021.13.17]
[4]
Jeevanandam J, Chan YS, Danquah MK. Nano-formulations of drugs: Recent developments, impact and challenges. Biochimie 2016; 128-129(9-10): 99-112.
[http://dx.doi.org/10.1016/j.biochi.2016.07.008] [PMID: 27436182]
[5]
Zhou X, Hao Y, Yuan L, et al. Nano-formulations for transdermal drug delivery: A review. Chin Chem Lett 2018; 29(12): 1713-24.
[http://dx.doi.org/10.1016/j.cclet.2018.10.037]
[6]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[7]
Watkins R, Wu L, Zhang C, Davis RM, Xu B. Natural product-based nanomedicine: Recent advances and issues. Int J Nanomedicine 2015; 10: 6055-74.
[PMID: 26451111]
[8]
Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: A mini review. Int Nano Lett 2014; 4: 94.
[http://dx.doi.org/10.1007/s40089-014-0094-7]
[9]
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015; 33(9): 941-51.
[http://dx.doi.org/10.1038/nbt.3330] [PMID: 26348965]
[10]
Shraddha M, Gowda DV, Vishal GN, Akhila AR. An overview on topical drug delivery systems – Updated review. Int J Res Pharm Sci 2020; 11(1): 368-85.
[http://dx.doi.org/10.26452/ijrps.v11i1.1831]
[11]
Raphael AP, Garrastazu G, Sonvico F, Prow TW. Formulation design for topical drug and nanoparticle treatment of skin disease. Ther Deliv 2015; 6(2): 197-216.
[http://dx.doi.org/10.4155/tde.14.106] [PMID: 25690087]
[12]
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: Classification, preparation, and applications. Nanoscale Res Lett 2013; 8(1): 102-9.
[http://dx.doi.org/10.1186/1556-276X-8-102]
[13]
Khoee S. Nanostructures for drug delivery niosomes: A novel approach in modern drug delivery systems. In: Nanostructures for Drug Delivery. 2017; pp. 207-37.
[14]
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharm Bull 2015; 5(3): 305-13.
[http://dx.doi.org/10.15171/apb.2015.043] [PMID: 26504751]
[15]
Verma P, Pathak K. Therapeutic and cosmeceutical potential of ethosomes: An overview. J Adv Pharm Technol Res 2010; 1(3): 274-82.
[http://dx.doi.org/10.4103/0110-5558.72415] [PMID: 22247858]
[16]
Ajazuddin A, Alexander A, Khichariya A, et al. Recent expansions in an emergent novel drug delivery technology: Emulgel. J Control Release 2013; 171(2): 122-32.
[http://dx.doi.org/10.1016/j.jconrel.2013.06.030] [PMID: 23831051]
[17]
Mohamed MI. Optimization of chlorphenesin emulgel formulation. AAPS J 2004; 6(3): e26.
[http://dx.doi.org/10.1208/aapsj060326] [PMID: 15760111]
[18]
Jain A, Deveda P, Vyas N, Chauhan J, Khambete H, Jain S. Development of antifungal emulsion based gel for topical fungal infection. IJPRD 2011; 2(12): 18-22.
[19]
Kasiramar GK, Komala S, Soundarya R, Parthiban S, Bharathi B, Elango S. Review on emulgel formulations with non-steroidal anti- inflammatory drugs for topical administration. Pharma Sci Monitor 2015; 8(1): 238-54.
[20]
Kale SN, Deore SL. Emulsion micro emulsion and nano emulsion: A review. Sys Rev Pharm 2017; 8(1): 39-47.
[http://dx.doi.org/10.5530/srp.2017.1.8]
[21]
Joshi B, Singh G, Rana AC, Saini S, Singla V. Emulgel: A comprehensive review on the recent advances in topical drug delivery. Int Res J Pharm 2011; 2: 66-70.
[22]
Panwar AS, Gandhi S, Sharma A, et al. Emulgel: A review. Asian J Pharm Life Sci 2011; 1(3): 333-43.
[23]
Kumar A, Ray S, Rahman M, et al. Nano-emulgel: Emerging as a smarter topical lipidic emulsion-based nanocarrier for skin healthcare applications. Recent Patents Anti-Infect Drug Disc 2019; 14(1): 16-35.
[24]
Devda P, Jain A, Vyas N, Khambete H, Jain S. Gellified emulsion for sustained delivery of itraconazole for topical fungal diseases. Int J Pharm Pharm Sci 2010; 2(1): 104-12.
[25]
Sreevidya VS. An overview on emulgel. Int J Pharm Phytopharm Res 2019; 9(1): 92-7.
[26]
Latha Samala M, Sridevi G. Role of polymers as gelling agents in the formulation of emulgels. Polym Sci 2016; 2(1): 1-8.
[http://dx.doi.org/10.4172/2471-9935.100010]
[27]
Yassin GE. Formulation and evaluation of optimized clotrimazole emulgel formulations. J Pharm Res Int 2014; 4(9): 1014-30.
[28]
Khunt DM, Mishra AD, Shah DR. Formulation design & development of piroxicam emulgel. Int J Pharm Tech Res 2012; 4(3): 1333-44.
[29]
Bhanu P, Vip Namakula S, Lakshmi PK. Development and optimization of novel diclofenac emulgel for topical drug delivery. Int J Compd Pharm 2011; 9(10): 1-4.
[30]
Banyal M, Joshi S. EMULGEL: An enormous approach for topical delivery of hydrophobic drugs. World J Pharm Res 2020; 9(13): 529-50.
[31]
Haneefa KPM, Easo S, Hafsa PV, Mohanta GP, Nayar I. Emulgel: An advanced review. Semantic Scholar 2013.
[32]
Sultana SS, Parveen P, Sri Rekha M, Deepthi K. Sowjanya Ch. A novel surrogate approach for transdermal drug delivery system. Indo Am J Pharm Res 2014; 4(11): 1462-77.
[33]
Guerrero DQ, Labat JP, Elvira SE, Romero GV. Pharmaceutical composition in ivermectin emulgel for veterinary use as a promoter system and bio-adhesive in antiparasitic treatment, and method for the production thereof. WO2016024855A1, 2014.
[34]
Hubei Keyi Pharmaceutic Co. Diclofenac diethylamine emulgel and preparation method thereof. CN102525886B 2012.
[35]
Yu Yuan Pharmaceutical Co. Glucosamine gel and preparation method thereof. CN102614111B, 2012.
[36]
Michel Steiger. Topical emulsion- gel composition comprising diclofenac sodium. WO2004017998A3, 2003.
[37]
van der Helm-van Mil AH, Breedveld FC, Huizinga TW. Aspects of early arthritis. Definition of disease states in early arthritis: Remission versus minimal disease activity. Arthritis Res Ther 2006; 8(4): 216.
[http://dx.doi.org/10.1186/ar1983] [PMID: 16879719]
[38]
www.mayoclinic.com/health/osteoarthritis
[39]
Mitra SP. Arthritis: Classification, nature & cause - A review. Am J Biopharmacol Biochem Life Sci 2013; 2: 1-19.
[40]
Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid arthritis: A brief overview of the treatment. Med Princ Pract 2018; 27(6): 501-7.
[http://dx.doi.org/10.1159/000493390] [PMID: 30173215]
[41]
Mitra SP. Pharmacology and biochemistry behind the use of natural herbs to control arthritis: A Review. Indian J Nat Prod Resour 2017; 8(3): 204-23.
[42]
Mahmood F, Helliwell P. Ankylosing spondylitis: A review. Eur Med J 2017; 2(4): 134-9.
[43]
Althoff CE, Hermann KG, Braun J, Sieper J. Ankylosierende Spondylitis. Z Rheumatol 2006; 65(8): 688-99.
[http://dx.doi.org/10.1007/s00393-006-0122-8] [PMID: 17119899]
[44]
Grossman JM. Lupus arthritis. Best Pract Res Clin Rheumatol 2009; 23(4): 495-506.
[http://dx.doi.org/10.1016/j.berh.2009.04.003] [PMID: 19591780]
[45]
Labowitz R, Schumacher HR Jr. Articular manifestations of systemic lupus erythematosus. Ann Intern Med 1971; 74(6): 911-21.
[http://dx.doi.org/10.7326/0003-4819-74-6-911] [PMID: 4931742]
[46]
Retrieved from: https://medlineplus.gov/infectiousarthritis.html
[47]
Retrieved from: https://www.niams.nih.gov/health-topics/juvenile-arthritis
[48]
Coates LC, Helliwell PS. Psoriatic arthritis: State of the art review. Clin Med 2017; 17(1): 65-70.
[http://dx.doi.org/10.7861/clinmedicine.17-1-65] [PMID: 28148584]
[49]
Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: Epidemiology and therapy. Osteoarthritis Res Soc Int 2020; 28(3): 242-8.
[http://dx.doi.org/10.1016/j.joca.2020.01.002] [PMID: 31945457]
[50]
Sebbag E, Felten R, Sagez F, Sibilia J, Devilliers H, Arnaud L. The world-wide burden of musculoskeletal diseases: A systematic analysis of the world health organization burden of diseases database. Ann Rheum Dis 2019; 78(6): 844-8.
[http://dx.doi.org/10.1136/annrheumdis-2019-215142] [PMID: 30987966]
[51]
Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J 2003; 79(933): 377-83.
[http://dx.doi.org/10.1136/pmj.79.933.377] [PMID: 12897215]
[52]
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis Lancet 2019; 393(10182): 1745-59.
[http://dx.doi.org/10.1016/S0140-6736(19)30417-9] [PMID: 31034380]
[53]
Retrieved from: https://www.webmd.com/osteoarthritis/medicines-treat-oa
[54]
Ma H, Li X, Zhou T, et al. Glucosamine use, inflammation, and genetic susceptibility, and incidence of type 2 diabetes: A prospective study in UK biobank. Diabetes Care 2020; 43(4): 719-25.
[http://dx.doi.org/10.2337/dc19-1836] [PMID: 31988063]
[55]
Barnhill JG, Fye CL, Reda DJ, Harris CL, Clegg DO. Is all glucosamine alike? Clarifying the controversies for product selection and clinical research. J Complement Integr Med 2019; 6(1)
[http://dx.doi.org/10.2202/1553-3840.1134]
[56]
European Pharmacopoeia. 2019.
[57]
Jerosch J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: Outlook on other nutrient partners especially omega-3 fatty acids. Int J Rheumatol 2011; 2011: 969012.
[http://dx.doi.org/10.1155/2011/969012] [PMID: 21826146]
[58]
Sahoo SC, Tharalekshmy A, Ng SW, Naumov P. Glucosamine salts: Resolving ambiguities over the market-based compositions. Cryst Growth Des 2012; 12(10): 5148-54.
[http://dx.doi.org/10.1021/cg301276y]
[59]
Retrieved from: https://www.lybrate.com/medicine/glucosamine-sulfate-potassium-chloride
[60]
Retrieved from: https://www.ashp.org/-/media/store%20files/p2418-sample-chapter-1.pdf
[61]
Altern Med Rev 1999; 4(3)
[62]
Retrieved from: https://www.webmd.com/vitamins/ai/ingredientmono-807/glucosamine-sulfate
[63]
Retrieved from: https://www.mayoclinic.org/drugs-supplements-glucosamine/art-20362874
[64]
Reginster JY, Bruyere O, Neuprez A. Current role of glucosamine in the treatment of osteoarthritis. Rheumatology (Oxford) 2007; 46(5): 731-5.
[http://dx.doi.org/10.1093/rheumatology/kem026] [PMID: 17401134]
[65]
Uitterlinden EJ, Jahr H, Koevoet JL, et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage 2006; 14(3): 250-7.
[http://dx.doi.org/10.1016/j.joca.2005.10.001] [PMID: 16300972]
[66]
Altman RD, Abramson S, Bruyere O, et al. Commentary: Osteoarthritis of the knee and glucosamine. Osteoarthritis Cartilage 2006; 14(10): 963-6.
[http://dx.doi.org/10.1016/j.joca.2006.06.010] [PMID: 16857394]
[67]
Reichelt A, Förster KK, Fischer M, Rovati LC, Setnikar I. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. Arzneimittelforschung 1994; 44(1): 75-80.
[PMID: 8135881]
[68]
Reginster JY, Neuprez A, Lecart MP, Sarlet N, Bruyere O. Role of glucosamine in the treatment for osteoarthritis. Rheumatol Int 2012; 32(10): 2959-67.
[http://dx.doi.org/10.1007/s00296-012-2416-2] [PMID: 22461188]
[69]
Müller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2(1): 61-9.
[http://dx.doi.org/10.1016/S1063-4584(05)80007-X] [PMID: 11548225]
[70]
Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung 1998; 48(5): 469-74.
[PMID: 9638313]
[71]
Wangroongsub Y, Tanavalee A, Wilairatana V, Ngarmukos S. Comparable clinical outcomes between glucosamine sulfate-potassium chloride and glucosamine sulfate sodium chloride in patients with mild and moderate knee osteoarthritis: A randomized, double-blind study. J Med Assoc Thai 2010; 93(7): 805-11.
[PMID: 20649060]
[72]
Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003; 30(3): 523-8.
[PMID: 12610812]
[73]
Jiangsu Aoxin Biotechnology Co Ltd. Preparation method of Dglucosamine sulfate potassium chloride salt. CN102850411A, 2012.
[74]
Pharma Base India Pvt Ltd. Process for preparing a mixed salt of glucosamine sulfate and an alkali metal chloride. CA2779168A1, 2009.
[75]
Xuzhou Haijiya Biological Products Co. Co-crystallization technology of glucosamine hydrochloride and glucosamine potassium/ sodium sulfate. CN101735283B, 2008.
[76]
Guangzhou Yipinhong Pharmaceutical Co. Compound glucosamine sulfate dispersible tablet formulation and its preparation method. CN1316978C, 2005.
[77]
Ali T, Nur PA, Secda T. Pharmaceutical composition comprising loxoprofen, glucosamine, chondroitin, hyaluronic acid for joint and cartilage disorders. WO2016156354A1, 2016.
[78]
Joar O. Substances for promoting healthy joint function comprising glucosamine sulfate, omega-3 polyunsaturated fatty acids or derivatives thereof, and undenatured type ii collagen. US20110217370A1, 2010.

Rights & Permissions Print Cite
Article Metrics
39
2
Wayfinder Image
International Day of People with Disability
© 2024 Bentham Science Publishers | Privacy Policy